Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
(ANTX) stock logo
ANTX
(ANTX)
$1.11
-9.4%
$0.00
$0.87
$3.07
$33.76M0.15366,658 shs83,337 shs
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$17.14
+0.4%
$13.33
$7.75
$19.93
$130.91M0.5526,240 shs18,229 shs
Korro Bio, Inc. stock logo
KRRO
Korro Bio
$12.46
-1.1%
$14.61
$10.29
$98.00
$117.01M2.45110,591 shs73,665 shs
Nkarta, Inc. stock logo
NKTX
Nkarta
$1.82
+0.6%
$1.87
$1.31
$8.23
$129.14M0.721.06 million shs430,106 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
(ANTX) stock logo
ANTX
(ANTX)
-6.36%-3.49%-5.56%-24.05%-44.75%
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
+0.35%+0.53%+24.20%+60.34%+15.19%
Korro Bio, Inc. stock logo
KRRO
Korro Bio
-1.11%-16.21%-20.69%-43.11%-62.93%
Nkarta, Inc. stock logo
NKTX
Nkarta
+0.55%-9.00%+7.06%+21.33%-65.46%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
(ANTX) stock logo
ANTX
(ANTX)
N/AN/AN/AN/AN/AN/AN/AN/A
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
3.9896 of 5 stars
3.35.00.04.71.30.80.0
Korro Bio, Inc. stock logo
KRRO
Korro Bio
2.5466 of 5 stars
3.63.00.00.03.20.00.6
Nkarta, Inc. stock logo
NKTX
Nkarta
3.4165 of 5 stars
4.63.00.00.02.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
(ANTX) stock logo
ANTX
(ANTX)
2.00
Hold$1.5035.75% Upside
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
2.67
Moderate Buy$33.0092.53% Upside
Korro Bio, Inc. stock logo
KRRO
Korro Bio
3.29
Buy$102.43722.06% Upside
Nkarta, Inc. stock logo
NKTX
Nkarta
3.13
Buy$14.33687.55% Upside

Current Analyst Ratings Breakdown

Latest ANTX, ASMB, NKTX, and KRRO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/10/2025
Nkarta, Inc. stock logo
NKTX
Nkarta
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$16.00 ➝ $14.00
5/15/2025
Nkarta, Inc. stock logo
NKTX
Nkarta
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform
5/15/2025
Nkarta, Inc. stock logo
NKTX
Nkarta
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$11.00 ➝ $10.00
5/13/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
5/13/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$155.00 ➝ $90.00
5/8/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$115.00 ➝ $100.00
5/5/2025
(ANTX) stock logo
ANTX
(ANTX)
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$5.00 ➝ $2.00
4/29/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$74.00
4/16/2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$25.00
4/9/2025
Nkarta, Inc. stock logo
NKTX
Nkarta
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
(ANTX) stock logo
ANTX
(ANTX)
N/AN/AN/AN/A$4.19 per shareN/A
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$28.52M4.59N/AN/A$5.25 per share3.26
Korro Bio, Inc. stock logo
KRRO
Korro Bio
$2.27M51.54N/AN/A$17.12 per share0.73
Nkarta, Inc. stock logo
NKTX
Nkarta
N/AN/AN/AN/A$5.78 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
(ANTX) stock logo
ANTX
(ANTX)
-$64.73M-$2.04N/AN/AN/AN/A-57.62%-52.08%N/A
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$40.18M-$6.23N/AN/AN/A-124.15%-131.77%-36.81%8/6/2025 (Estimated)
Korro Bio, Inc. stock logo
KRRO
Korro Bio
-$83.58M-$9.44N/AN/AN/AN/A-51.64%-37.94%8/12/2025 (Estimated)
Nkarta, Inc. stock logo
NKTX
Nkarta
-$108.79M-$1.51N/AN/AN/AN/A-26.64%-21.62%8/12/2025 (Estimated)

Latest ANTX, ASMB, NKTX, and KRRO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Nkarta, Inc. stock logo
NKTX
Nkarta
-$0.44-$0.43+$0.01-$0.43N/AN/A
5/8/2025Q1 2025
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$2.01-$1.17+$0.84-$1.17$7.41 million$9.42 million
5/7/2025Q1 2025
Korro Bio, Inc. stock logo
KRRO
Korro Bio
-$2.60-$2.49+$0.11-$2.49$0.13 million$2.55 million
3/26/2025Q4 2024
Nkarta, Inc. stock logo
NKTX
Nkarta
-$0.41-$0.35+$0.06-$0.35N/AN/A
3/20/2025Q4 2024
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$1.75-$1.57+$0.18-$1.57$7.05 million$7.36 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
(ANTX) stock logo
ANTX
(ANTX)
N/AN/AN/AN/AN/A
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/AN/AN/AN/AN/A
Korro Bio, Inc. stock logo
KRRO
Korro Bio
N/AN/AN/AN/AN/A
Nkarta, Inc. stock logo
NKTX
Nkarta
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
(ANTX) stock logo
ANTX
(ANTX)
N/A
9.75
9.75
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/A
2.05
2.05
Korro Bio, Inc. stock logo
KRRO
Korro Bio
N/A
9.41
9.41
Nkarta, Inc. stock logo
NKTX
Nkarta
N/A
14.48
14.48

Institutional Ownership

CompanyInstitutional Ownership
(ANTX) stock logo
ANTX
(ANTX)
90.47%
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
19.92%
Korro Bio, Inc. stock logo
KRRO
Korro Bio
13.18%
Nkarta, Inc. stock logo
NKTX
Nkarta
80.54%

Insider Ownership

CompanyInsider Ownership
(ANTX) stock logo
ANTX
(ANTX)
20.79%
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
5.30%
Korro Bio, Inc. stock logo
KRRO
Korro Bio
4.60%
Nkarta, Inc. stock logo
NKTX
Nkarta
8.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
(ANTX) stock logo
ANTX
(ANTX)
N/A29.88 million23.67 millionNot Optionable
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
1007.64 million7.23 millionOptionable
Korro Bio, Inc. stock logo
KRRO
Korro Bio
709.39 million8.96 millionNo Data
Nkarta, Inc. stock logo
NKTX
Nkarta
14070.96 million65.00 millionOptionable

Recent News About These Companies

Mizuho Lowers Nkarta (NASDAQ:NKTX) Price Target to $14.00

New MarketBeat Followers Over Time

Media Sentiment Over Time

(ANTX) stock logo

(ANTX) NYSE:ANTX

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Assembly Biosciences stock logo

Assembly Biosciences NASDAQ:ASMB

$17.14 +0.06 (+0.35%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$17.18 +0.04 (+0.20%)
As of 06/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Korro Bio stock logo

Korro Bio NASDAQ:KRRO

$12.46 -0.14 (-1.11%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$12.48 +0.01 (+0.12%)
As of 06/18/2025 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Nkarta stock logo

Nkarta NASDAQ:NKTX

$1.82 +0.01 (+0.55%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$1.83 +0.01 (+0.77%)
As of 06/18/2025 05:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.